{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:01:02Z","timestamp":1774616462366,"version":"3.50.1"},"reference-count":64,"publisher":"Ubiquity Press, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["gh"],"abstract":"<jats:p>Background: Despite clear guidelines for lipid-lowering therapies (LLT) for patients with high and very-high atherosclerotic cardiovascular disease (ASCVD) risk, a significant gap persists between recommended low-density lipoprotein cholesterol (LDL-C) management and actual clinical practice, leaving a large proportion of patients without adequate treatment. Patient age is one of several factors that may play a role in this gap.\nObjectives: We characterized LLT prescription patterns among middle-aged and older adults with high and very-high ASCVD risk and estimated the effect of age in achieving LDL-C control.\nMethods: This cohort study used electronic health records of a Portuguese healthcare institution from January 2012 to December 2022. Middle-aged (40\u201369 years) and older (70\u201385 years) patients with high and very-high ASCVD risk were analysed. Exposure consisted of LLT prescriptions. LLT prescriptions were characterized in six dynamic patterns based on statin intensity (high, moderate, low) and the addition of ezetimibe. Risk for LDL-C control at 150 and 360 days was compared between the two age cohorts using multivariate Cox regressions.\nResults: A total of 36,866 patients were identified, accounting for 407,500 LLT prescriptions. High-intensity statins were more frequently prescribed to middle-aged patients (12.0% vs. 8.6% older), whereas older patients more often received low-intensity statins (8.6% vs. 5.9% middle-aged). The use of statin-ezetimibe combinations was low across all age groups (0.1\u20131.4%). At 150 and 360 days of follow-up, LDL-C targets were achieved in 2,661 (0.7%) and 14,047 (3.8%) prescriptions, respectively. Older patients had a 32% higher rate of reaching LDL-C goals at 150 days (HR = 1.32, 95% CI = 1.19\u20131.45) and 27% at 360 days (HR = 1.27, 95% CI = 1.19\u20131.35).\nConclusion: LDL-C control remains low in high- and very-high-risk patients from a Portuguese integrated health care unit, with particularly low achievement rates among middle-aged adults, despite their higher use of high-intensity LLT. These findings highlight the need for optimized treatment strategies, including age-specific approaches.<\/jats:p>","DOI":"10.5334\/gh.1543","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:10:02Z","timestamp":1774613402000},"page":"29","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Age on Lipid-Lowering Therapy Prescriptions and LDL-Cholesterol Control: Insights from the PORTRAIT-DYS Study"],"prefix":"10.5334","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2553-8264","authenticated-orcid":false,"given":"Cristina","family":"Gavina","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-9341","authenticated-orcid":false,"given":"Daniel","family":"Seabra","sequence":"additional","affiliation":[]},{"given":"S\u00edlvia","family":"Oliveira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8255-3795","authenticated-orcid":false,"given":"Carla","family":"Teixeira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3219-4028","authenticated-orcid":false,"given":"Jorge A.","family":"Ruivo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8133-4667","authenticated-orcid":false,"given":"Nuno","family":"Louren\u00e7o-Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5406-0991","authenticated-orcid":false,"given":"Ana Rita","family":"Luz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-8791","authenticated-orcid":false,"given":"Cristina","family":"J\u00e1come","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6224-4866","authenticated-orcid":false,"given":"Francisco","family":"Ara\u00fajo","sequence":"additional","affiliation":[]}],"member":"3285","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"key20260327120957_B1","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"key20260327120957_B2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"key":"key20260327120957_B3","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key20260327120957_B4","article-title":"Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement","volume":"10","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"key20260327120957_B5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: From plaques to genes to statins","volume":"161","year":"2015","journal-title":"Cell"},{"key":"key20260327120957_B6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/jnci\/djr008","article-title":"Low-density lipoprotein cholesterol and the risk of cancer: A Mendelian randomization study","volume":"103","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key20260327120957_B7","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","year":"2007","journal-title":"Lancet"},{"key":"key20260327120957_B8","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis","volume":"60","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key20260327120957_B9","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archinte.1992.00400190110021","article-title":"Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group","volume":"152","year":"1992","journal-title":"Arch Intern Med"},{"key":"key20260327120957_B10","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archinte.1981.00340090024008","article-title":"Lipoproteins, cardiovascular disease, and death","volume":"141","year":"1981","journal-title":"Arch Intern Med"},{"key":"key20260327120957_B11","article-title":"Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"2016","year":"2016","journal-title":"Glob Cardiol Sci Pract"},{"key":"key20260327120957_B12","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/eurheartj\/ehr333","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K","volume":"32","author":"ASCOT Investigators","year":"2011","journal-title":"Eur Heart J"},{"key":"key20260327120957_B13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(02)08351-4","article-title":"Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up","volume":"359","author":"LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)","year":"2002","journal-title":"Lancet"},{"key":"key20260327120957_B14","unstructured":"Noncommunicable Diseases Global Monitoring Framework: Indicator Definitions and Specifications. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/inaugural-who-partners-forum\/gmf_indicator_definitions_version_nov2014438a791b-16d3-46f3-a398-88dee12e796b.pdf?sfvrsn=4b337764_1&download=true. Accessed 21 Jan 2026."},{"key":"key20260327120957_B15","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: A systematic review and meta-analysis of randomised controlled trials","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"key20260327120957_B16","first-page":"e285","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","year":"2019","journal-title":"Circulation"},{"key":"key20260327120957_B17","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"key":"key20260327120957_B18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S0140-6736(21)02347-3","article-title":"NCD Countdown 2030: Efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries","volume":"399","author":"NCD Countdown 2030 Collaborators","year":"2022","journal-title":"Lancet"},{"key":"key20260327120957_B19","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1080\/03007995.2021.1973396","article-title":"Lipid management across Europe in the real-world setting: A rapid evidence review","volume":"37","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"key20260327120957_B20","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"key20260327120957_B21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: The DA VINCI study","volume":"28","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"key20260327120957_B22","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1177\/2047487318806359","article-title":"Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe","volume":"25","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"key20260327120957_B23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.atherosclerosis.2018.02.024","article-title":"Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice","volume":"271","year":"2018","journal-title":"Atherosclerosis"},{"key":"key20260327120957_B24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s12325-019-0879-1","article-title":"Clinical management of high and very high risk patients with hyperlipidaemia in central and eastern Europe: An observational study","volume":"36","year":"2019","journal-title":"Adv Ther"},{"key":"key20260327120957_B25","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key20260327120957_B26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey","volume":"246","year":"2016","journal-title":"Atherosclerosis"},{"key":"key20260327120957_B27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.athplu.2021.08.003","article-title":"Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe \u2013 Methodology and rationale for the multinational observational SANTORINI study","volume":"43","year":"2021","journal-title":"Atheroscler Plus"},{"key":"key20260327120957_B28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","article-title":"Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients","volume":"255","year":"2016","journal-title":"Atherosclerosis"},{"key":"key20260327120957_B29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","year":"2019","journal-title":"Atherosclerosis"},{"key":"key20260327120957_B30","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"key20260327120957_B31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","year":"2006","journal-title":"JAMA"},{"key":"key20260327120957_B32","article-title":"Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: A systematic review","volume":"3","year":"2016","journal-title":"Open Heart"},{"key":"key20260327120957_B33","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"key20260327120957_B34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pds.4295","article-title":"Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0","volume":"26","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20260327120957_B35","unstructured":"INE. Indicadores. Available from: https:\/\/tabulador.ine.pt\/censos2021\/. Accessed 5 Mar 2025."},{"key":"key20260327120957_B36","volume-title":"Guidelines ATC Classification DDD Assignment","author":"WHO Collaborating Centre Drug Statistics Methodology","year":"2022"},{"key":"key20260327120957_B37","first-page":"2889","article-title":"Reprint: 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"63","year":"2013","journal-title":"J Am Pharm Assoc (2003)"},{"key":"key20260327120957_B38","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"key":"key20260327120957_B39","article-title":"Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study","volume":"384","year":"2023","journal-title":"Atherosclerosis"},{"key":"key20260327120957_B40","unstructured":"OMOP CDM v5.3. Available from: https:\/\/ohdsi.github.io\/CommonDataModel\/cdm53.html. Accessed 4 Nov 2024."},{"key":"key20260327120957_B41","unstructured":"Therneau TM. A package for survival analysis in R (survival package). Vienna: R Foundation for Statistical Computing; 2024. Available from: https:\/\/vps.fmvz.usp.br\/CRAN\/web\/packages\/survival\/survival.pdf. Accessed 4 Nov 2024."},{"key":"key20260327120957_B42","unstructured":"Online T. A High-Level grammar of interactive graphics. Vega-Lite. Available from: https:\/\/vega.github.io\/vega-lite\/. Accessed 4 Nov 2024."},{"key":"key20260327120957_B43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2017.08.014","article-title":"Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database","volume":"265","year":"2017","journal-title":"Atherosclerosis"},{"key":"key20260327120957_B44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)","volume":"105","year":"2010","journal-title":"Am J Cardiol"},{"key":"key20260327120957_B45","article-title":"Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study","volume":"47","year":"2024","journal-title":"Clin Cardiol"},{"key":"key20260327120957_B46","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study","volume":"29","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"key20260327120957_B47","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: The DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u20131289. Available from: https:\/\/academic.oup.com\/eurjpc\/article\/28\/11\/1279\/5898664. Accessed 21 Jan 2026."},{"key":"key20260327120957_B48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2019","journal-title":"Lancet"},{"key":"key20260327120957_B49","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0735-1097(02)02477-4","article-title":"Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients","volume":"40","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"key20260327120957_B50","article-title":"Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: A systematic review and meta-analysis of observational studies","volume":"19","year":"2021","journal-title":"BMC Med"},{"key":"key20260327120957_B51","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-152-8-201004200-00005","article-title":"Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial","volume":"152","year":"2010","journal-title":"Ann Intern Med"},{"key":"key20260327120957_B52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2007.06.063","article-title":"Statins for secondary prevention in elderly patients: A hierarchical bayesian meta-analysis","volume":"51","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key20260327120957_B53","article-title":"Statin use and adverse effects among adults >75 years of age: Insights from the Patient and Provider Assessment of Lipid Management (PALM) registry","volume":"7","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"key20260327120957_B54","article-title":"Initiation rates of statin therapy for the primary prevention of cardiovascular disease: An assessment of differences between countries of the UK and between regions within England","volume":"5","year":"2015","journal-title":"BMJ Open"},{"key":"key20260327120957_B55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: Insights from the Medical Expenditure Panel Survey","volume":"2","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key20260327120957_B56","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/eht368","article-title":"Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key20260327120957_B57","first-page":"1270","article-title":"Ezetimibe use and LDL-C goal achievement: A retrospective database analysis of patients with clinical atherosclerotic cardiovascular disease or probable heterozygous familial hypercholesterolemia","volume":"23","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"key20260327120957_B58","article-title":"Ezetimibe use and mortality after myocardial infarction: A nationwide cohort study","volume":"19","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"key20260327120957_B59","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jacc.2015.08.042","article-title":"Trends in the use of nonstatin lipid-lowering therapy among patients with coronary heart disease: A retrospective cohort study in the Medicare population 2007 to 2011","volume":"66","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key20260327120957_B60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/clc.22338","article-title":"Statins in the elderly: A patient-focused approach","volume":"38","year":"2015","journal-title":"Clin Cardiol"},{"key":"key20260327120957_B61","article-title":"Age-related associations of low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease: A nationwide population-based cohort study","volume":"11","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"key20260327120957_B62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.atherosclerosis.2021.02.024","article-title":"Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: A large-scale, cross-sectional study in primary care","volume":"324","year":"2021","journal-title":"Atherosclerosis"},{"key":"key20260327120957_B63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"key20260327120957_B64","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","year":"2016","journal-title":"Eur J Prev Cardiol"}],"container-title":["Global Heart"],"original-title":[],"link":[{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1543\/2284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1543\/2285","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1543\/2286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1543\/2284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:13:44Z","timestamp":1774613624000},"score":1,"resource":{"primary":{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/view\/1543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,14]]}},"URL":"https:\/\/doi.org\/10.5334\/gh.1543","relation":{},"ISSN":["2211-8179","2211-8160"],"issn-type":[{"value":"2211-8179","type":"electronic"},{"value":"2211-8160","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}